Ascletis Pharma Inc.

Investors

Voluntary Announcement - Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
2026-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
2026-08-04
Voluntary Announcement - Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
2026-08-03
Notice of Board Meeting
2026-08-03
Next Day Disclosure Returns - Share Buyback
2026-07-30
Next Day Disclosure Returns - Share Buyback
2026-07-29
Next Day Disclosure Returns - Share Buyback
2026-07-28
Voluntary Announcement - Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
2026-07-27
Next Day Disclosure Returns - Share Buyback
2026-07-27
Next Day Disclosure Returns - Share Buyback
2026-07-24

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1 Cookie Settings